AMRN Amarin Corporation plc - American Depositary Shares
$14,37
Prezzo · Ago 19, 2026
Fondamentali al Lug 29, 2026
Intervallo 52 sett.
$13–$21
18% of range
Rating Analisti
HOLD
6 analysts
Prezzo Obiettivo
$12
P/E (TTM)
-159.7
ROE
-8.4%
Margine di Profitto Netto
-18.2%
Informazioni su Amarin Corporation plc - American Depositary Shares Panoramica della società da Wikipedia
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Leggi di più
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval, competing against GlaxoSmithKline's Lovaza.
History
Amarin Corporation plc (formerly Ethical Holdings plc) was originally incorporated in England as a private limited company on March 1, 1989, and later re-registered as a public company on March 19, 1993. In 2002, the company suffered losses worth $37 million; 2003 losses exceeded $19 million. As of 2005, it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.
In December 2007, Amarin acquired Ester Neurosciences Limited for US$8.1 million. In 2011, CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.
Products and development
Vascepa (USA) / Vazkepa (EU)
Amarin´s sole product VASCEPA® came on the market in 2013 for triglyceride levels >=500 milligrams per deciliter. In December 2019, the FDA approved "...the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease....Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
Furthermore, VASCEPA® is in use in clinical trials by 3rd parties to see, if it has an effect on Alzheimer, Colon Cancer, Nonalcoholic Steatohepatitis (NASH), and other diseases.
HLS Therapeutics, Amarin´s license partner in Canada, presented results of their COVID-19 clinical trial for Vascepa at National Lipid Association Scientific Sessions 2020, December 12. The results demonstrated a 25% reduction of hs-CRP, a biomarker for inflammation. Most people with COVID-19 die, because of a cytokine storm, which causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines. Two more COVID-19 studies are actually running with Vascepa to validate and proof further benefits.
On January 28, the Committee for Medicinal Products for Human Use gave a positive recommendation for Vazcepa (its name in the EU), which the European Commission finally approved on March 30.
Patent disputes
On March 30, 2020, the designated patent judge in the U.S. District Court for the District of Nevada, Miranda Du, ruled for generic-drug makers Hikma Pharmaceuticals and Dr. Reddy's Laboratories in a lawsuit with Amarin over patents on Amarin's drug, Vascepa. Soon after, on April 2, 2020, Amarin filed an appeal of the ruling. The appeal was lost and an en-banc was also not granted, afterwards. On November 30, three weeks after Hikma Pharmaceuticals started the distribution of their generic version of Vascepa, Amarin filed a complaint of patent infringement against Hikma. On February 11, 2021, Amarin filed a petition for certiorari with the US Supreme Court. On June 21, 2021, the petition was denied.
== Finance ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
AMRN Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$14.37
Capitalizzazione di Mercato
$5.98B
P/E (TTM)
-159.7
EPS (TTM)
$-0.09
Ricavi (TTM)
$214M
Rendimento div.
—
ROE
-8.4%
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$13 – $21
AMRN Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$214M
2016-12-31
→
2025-12-31
EPS
$-0.09
2016-12-31
→
2025-12-31
Flusso di cassa libero
—
2016-12-31
→
2020-12-31
Margini
-18.2%
2016-12-31
→
2025-12-31
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
AMRN
Mediana dei peer
P/E (TTM)
-159.7
55.9
P/S (TTM)
28.0
5.5
P/B
13.0
1.8
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
AMRN
Mediana dei peer
Gross Margin (Margine lordo)
56.6%
63.8%
Operating Margin (Margine Operativo)
-23.5%
—
Net Profit Margin (Margine di Profitto Netto)
-18.2%
-14.2%
ROA
-5.7%
-4.2%
ROE
-8.4%
-6.0%
ROIC
-11.8%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
AMRN
Mediana dei peer
Current Ratio (Rapporto corrente)
3.3
3.7
Quick Ratio
2.2
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
AMRN
Mediana dei peer
Revenue YoY (Ricavi YoY)
-6.6%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
-16.7%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
-19.0%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
AMRN
Mediana dei peer
AMRN Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
VENDI
6 analisti
- Acquisto forte 0 0,0%
- Compra 0 0,0%
- Mantieni 2 33,3%
- Vendi 2 33,3%
- Vendita forte 2 33,3%
Target Price a 12 Mesi
1 analisti · 2026-08-15
Basso
$12.00
Alto
$12.00
Target mediano
$12.00
-16,5%
Target medio
$12.00
-16,5%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.20%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $0.04 | $-0.01 | 0.05% |
| 31 Marzo 2026 | $-0.09 | $0.09 | -0.18% |
| 31 Dicembre 2025 | $0.01 | $0.00 | 0.01% |
| 30 Settembre 2025 | $0.08 | $-0.58 | 0.66% |
| 30 Giugno 2025 | $0.66 | $-0.18 | 0.84% |
| 31 Marzo 2025 | $-0.76 | $-0.58 | -0.18% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| AMRN | $5.81B | -155.1 | -6.6% | -18.2% | -8.4% | 56.6% |
| ALKS | $4.63B | 19.6 | -5.2% | 16.4% | 14.0% | — |
| PRTA | $514M | -2.1 | -92.8% | -2520.6% | -63.6% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 18
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Cost of Revenue | · | · | · | · | $121M | $131M | $96M | $55M | $45M | $34M | $28M | $20M | |
| Gross Profit | $121M | $81M | $166M | $242M | $462M | $483M | $334M | $175M | $136M | $96M | $54M | $34M | |
| R&D Expense | $20M | $21M | $22M | $30M | $29M | $39M | $34M | $56M | $47M | $50M | $51M | $50M | |
| SG&A Expense | $115M | $152M | $200M | $304M | $408M | $463M | $324M | $227M | $135M | $111M | $101M | $79M | |
| Operating Expenses | $171M | $173M | $233M | $348M | $451M | $502M | $358M | $283M | $182M | $161M | $152M | $130M | |
| Operating Income | $-50M | $-92M | $-68M | $-106M | $11M | $-20M | $-24M | $-108M | $-46M | $-66M | $-98M | $-96M | |
| Interest Expense | $7.0K | $7.0K | $8.0K | $15.0K | $129.0K | $3M | $7M | $9M | $10M | $19M | $20M | $19M | |
| Interest Income | $11M | $13M | $12M | $3M | $1M | $5M | $8M | $1M | $429.0K | $234.0K | $132.0K | $96.0K | |
| Other Non-op | $3M | $1M | $2M | $-740.0K | $-302.0K | $104.0K | $-75.0K | $-326.0K | $74.0K | $-482.0K | $-228.0K | $4M | |
| Pretax Income | $-36M | $-77M | $-54M | $-104M | $11M | $-17M | $-22M | $-116M | $-55M | $-76M | $-118M | $-59M | |
| Income Tax | $3M | $5M | $5M | $2M | $4M | $745.0K | $164.0K | $96.0K | $13M | $10M | $-3M | $-3M | |
| Net Income | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| EPS (Basic) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.32 | |
| EPS (Diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 | $-0.83 | $-0.36 | |
| Shares (Basic) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 395,992,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,719,000 | |
| Shares (Diluted) | 414,984,000 | 410,937,000 | 407,655,000 | 401,155,000 | 402,480,000 | 381,759,000 | 342,538,000 | 297,237,000 | 270,652,000 | 211,874,000 | 180,654,000 | 173,824,000 | |
| EBITDA | $-50M | $-92M | $-68M | · | · | $-20M | · | $-108M | $-46M | $-66M | $-98M | $-96M |
Stato Patrimoniale 27
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $135M | $121M | $199M | $218M | $219M | $187M | $645M | $249M | $74M | $98M | $107M | $120M | |
| Short-term Investments | $168M | $173M | $121M | $92M | $235M | $314M | · | · | · | · | · | · | |
| Receivables | $127M | $122M | $134M | $131M | $164M | $155M | $116M | $67M | $45M | $20M | $14M | $8M | |
| Inventory | $196M | $166M | $259M | $229M | $235M | $189M | $77M | $58M | $30M | $21M | $19M | $14M | |
| Prepaid Expense | $24M | $13M | $12M | $19M | $22M | $31M | $13M | $3M | $3M | $7M | $3M | $3M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Assets | $650M | $595M | $725M | $689M | $879M | $879M | $855M | $378M | $153M | $146M | $144M | $145M | |
| PP&E (Net) | $12.0K | $16.0K | $114.0K | $874.0K | $1M | $2M | $2M | $63.0K | $28.0K | $78.0K | $243.0K | $381.0K | |
| PP&E (Gross) | $1M | $1M | $1M | $3M | $3M | $4M | $3M | $902.0K | $844.0K | $821.0K | $997.0K | $969.0K | |
| Accum. Depreciation | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $839.0K | $816.0K | $755.0K | $754.0K | $588.0K | |
| Intangibles | $13M | $16M | $19M | $22M | $24M | $14M | $15M | $7M | $8M | $9M | $9M | $10M | |
| Other Non-current Assets | $1M | $1M | $1M | $458.0K | $456.0K | $432.0K | $1M | $174.0K | $174.0K | $741.0K | $174.0K | $3M | |
| Total Assets | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Accounts Payable | $45M | $40M | $53M | $65M | $115M | $106M | $50M | $38M | $25M | $6M | $11M | $9M | |
| Current Liabilities | $194M | $180M | $259M | $259M | $371M | $307M | $242M | $157M | $109M | $76M | $51M | $40M | |
| Capital Leases | $6M | $8M | $9M | $10M | $9M | $9M | $9M | · | · | · | · | · | |
| Other Non-current Liabilities | $11M | $12M | $9M | $8M | $8M | $6M | $4M | $11M | $1M | $710.0K | $335.0K | $386.0K | |
| Total Liabilities | $211M | $199M | $280M | $291M | $401M | $339M | $274M | $233M | $227M | $176M | $301M | $260M | |
| Long-term Debt | · | · | · | · | · | · | $50M | $80M | $92M | $94M | $92M | $105M | |
| Total Debt | · | · | · | · | · | $0 | · | $80M | $93M | $101M | $106M | $105M | |
| Common Stock | $310M | $305M | $303M | $299M | $294M | $290M | $269M | $247M | $209M | $207M | $150M | $143M | |
| Paid-in Capital | $1.92B | $1.91B | $1.90B | $1.89B | $1.86B | $1.82B | $1.76B | $1.28B | $978M | · | · | · | |
| Retained Earnings | $-1.71B | $-1.67B | $-1.59B | $-1.53B | $-1.42B | $-1.43B | $-1.41B | $-1.39B | $-1.27B | $-1.20B | $-1.12B | $-970M | |
| Treasury Stock | $67M | $65M | $64M | $62M | $61M | $51M | $36M | $10M | $4M | $1M | $411.0K | $217.0K | |
| Stockholders' Equity | $459M | $486M | $552M | $595M | $667M | $628M | $608M | $152M | $-65M | $-9M | $-129M | $-88M | |
| Liabilities + Equity | $671M | $685M | $832M | $886M | $1.07B | $966M | $882M | $386M | $162M | $167M | $173M | $171M | |
| Shares Outstanding | 416,214,102 | 411,584,851 | 408,824,093 | 408,824,093 | 396,598,008 | 392,538,081 | 360,103,901 | 325,850,013 | 271,022,011 | 269,363,696 | 183,403,263 | 174,590,372 |
Flusso di cassa 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $23.0K | $62.0K | $138.0K | $166.0K | $198.0K | |
| Stock-based Comp | $14M | $18M | $16M | $26M | $37M | $46M | $31M | $19M | $14M | $14M | $14M | $9M | |
| Deferred Tax | · | · | · | · | · | · | · | · | $11M | $9M | $-4M | $-4M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $2M | $1M | $679.0K | $646.0K | $646.0K | $645.0K | $646.0K | $646.0K | |
| Restructuring | $36M | $0 | $11M | $14M | $14M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $7M | $-31M | $7M | $-180M | $-67M | $-22M | $-9M | $-95M | $-33M | $-72M | $-84M | $-75M | |
| CapEx | · | · | · | · | · | $252.0K | $2M | $58.0K | $12.0K | $21.0K | $28.0K | · | |
| Investing Cash Flow | $9M | $-46M | $-26M | $175M | $104M | $-377M | $-2M | $-58.0K | $-12.0K | $-21.0K | · | · | |
| Net Debt Issued | · | · | · | · | · | $-50M | · | $-15M | $-3M | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $440M | $265M | · | $65M | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $194.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | $265M | · | $65M | $-194.0K | · | |
| Financing Cash Flow | $-2M | $-1M | $230.0K | $-379.0K | $-5M | $-59M | $410M | $271M | $8M | $63M | · | · | |
| Net Change in Cash | $14M | $-78M | $-18M | $-5M | $32M | $-458M | $398M | $176M | $-25M | $-9M | $-13M | $-72M | |
| Taxes Paid | $1M | $4M | $2M | $-2M | $4M | $-207.0K | $-67.0K | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-22M | · | $-95M | $-33M | $-72M | $-85M | · | |
| Levered FCF | · | · | · | · | · | $-25M | · | $-104M | $-45M | $-93M | $-104M | · |
Redditività 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 35.6% | 53.9% | · | · | 78.6% | · | 76.2% | 75.2% | 73.6% | 65.9% | 62.2% | |
| Operating Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| Net Margin | -18.2% | -35.9% | -19.3% | · | · | -2.9% | · | -50.8% | -37.5% | -66.4% | -140.9% | -104.0% | |
| Pretax Margin | -16.9% | -33.8% | -17.5% | · | · | -2.8% | · | -50.8% | -30.3% | -58.7% | -144.7% | -109.2% | |
| EBITDA Margin | -23.5% | -40.2% | -22.0% | · | · | -3.2% | · | -47.2% | -25.1% | -50.4% | -120.1% | -177.0% | |
| ROA | -5.7% | -10.8% | -6.9% | · | · | -1.9% | · | -42.5% | -41.3% | -50.8% | -66.9% | -26.6% | |
| ROE | -8.4% | -16.2% | -10.7% | · | · | -2.9% | · | -234.1% | 183.0% | 124.9% | 105.9% | 92.2% | |
| ROIC | -11.8% | -20.1% | -13.5% | · | · | -3.3% | · | -46.6% | -200.8% | -80.6% | 417.0% | -551.6% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.3 | 2.8 | · | · | 2.9 | · | 2.4 | 1.4 | 1.9 | 2.8 | 3.6 | |
| Quick Ratio | 2.2 | 2.3 | 1.8 | · | · | 2.1 | · | 2.0 | 1.1 | 1.6 | 2.4 | 3.2 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.5 | -1.4 | -11.2 | -0.8 | -1.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.3 | -1.1 | -9.4 | -0.7 | -1.0 | |
| Interest Coverage | -7167.1 | -13113.9 | -8448.5 | · | · | -7.5 | · | -12.2 | -4.7 | -3.5 | -4.9 | -5.2 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.4 | · | · | 0.7 | · | 0.8 | 1.1 | 0.8 | 0.5 | 0.3 | |
| Inventory Turnover | · | · | · | · | · | 1.0 | · | 1.2 | 1.8 | 1.7 | 1.7 | 1.2 | |
| Receivables Turnover | 1.7 | 1.8 | 2.3 | · | · | 4.5 | · | 4.1 | 5.5 | 7.7 | 7.5 | 9.4 |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -6.6% | -25.5% | -16.9% | -36.7% | -5.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -16.7% | -26.8% | -20.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -19.0% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M | $82M | $54M | |
| Net Income TTM | $-39M | $-82M | $-59M | $-106M | $8M | $-18M | $-23M | $-116M | $-68M | $-86M | $-115M | $-56M | |
| Market Cap | $5.81B | $4.03B | $7.11B | · | · | $38.39B | · | $88.70B | $21.74B | $16.59B | $6.93B | $3.42B | |
| Enterprise Value | · | · | · | · | · | $37.89B | · | $88.53B | $21.76B | $16.60B | $6.93B | $3.41B | |
| P/E | -155.1 | -49.0 | -116.0 | -93.1 | 3370.0 | -1956.0 | -6125.7 | -697.9 | -320.8 | -150.2 | -45.5 | -54.4 | |
| P/S | 27.2 | 17.6 | 23.2 | · | · | 62.5 | · | 387.0 | 120.0 | 127.6 | 84.8 | 63.1 | |
| P/B | 12.7 | 8.3 | 12.9 | · | · | 61.2 | · | 582.3 | -333.9 | -1831.8 | -53.7 | -38.7 | |
| P / Tangible Book | 13.0 | 8.6 | 13.4 | 17.1 | 41.5 | 62.6 | · | · | · | · | · | · | |
| P / Cash Flow | 863.6 | -130.0 | 1033.9 | · | · | -1765.4 | · | -936.6 | -661.9 | -231.0 | -81.8 | -47.3 | |
| P / FCF | · | · | · | · | · | -1745.2 | · | -936.0 | -661.7 | -231.0 | -81.8 | · | |
| EV / EBITDA | · | · | · | · | · | -1927.7 | · | -818.0 | -477.6 | -252.9 | -70.6 | -35.5 | |
| EV / FCF | · | · | · | · | · | -1722.4 | · | -934.2 | -662.3 | -231.0 | -81.8 | · | |
| EV / Revenue | · | · | · | · | · | 61.7 | · | 386.2 | 120.1 | 127.6 | 84.8 | 62.9 | |
| Earnings Yield | -0.64% | -2.0% | -0.86% | -1.1% | 0.03% | -0.05% | -0.02% | -0.14% | -0.31% | -0.67% | -2.2% | -1.8% |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42M | $45M | $49M | $50M | $73M | $42M | $62M | $42M | $67M | $57M | $75M | $66M | $80M | $86M | $90M | $90M | |
| Gross Profit | $15M | $18M | $23M | $22M | $50M | $25M | $-10M | $16M | $43M | $32M | $45M | $30M | $43M | $48M | $64M | $63M | |
| R&D Expense | $5M | $5M | $5M | $4M | $5M | $5M | $6M | $5M | $5M | $6M | $6M | $5M | $6M | $6M | $5M | $6M | |
| SG&A Expense | $22M | $21M | $20M | $20M | $39M | $37M | $37M | $37M | $39M | $40M | $44M | $45M | $51M | $60M | $68M | $59M | |
| Operating Expenses | $27M | $29M | $29M | $33M | $66M | $42M | $43M | $41M | $43M | $45M | $50M | $51M | $67M | $65M | $73M | $68M | |
| Operating Income | $-12M | $-11M | $-6M | $-11M | $-16M | $-17M | $-53M | $-25M | $-524.0K | $-14M | $-5M | $-21M | $-24M | $-17M | $-10M | $-5M | |
| Interest Income | $3M | $2M | · | · | $3M | $3M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $1M | $188.0K | $3M | $205.0K | $-85.0K | $253.0K | $-754.0K | $265.0K | $145.0K | $2M | $-1M | $-575.0K | $3M | $624.0K | $1M | $511.0K | |
| Pretax Income | $-8M | $-9M | $-853.0K | $-8M | $-13M | $-14M | $-50M | $-22M | $3M | $-9M | $-2M | $-19M | $-18M | $-14M | $-7M | $-4M | |
| Income Tax | $-219.0K | $2M | $371.0K | $-377.0K | $689.0K | $2M | $-1M | $4M | $1M | $1M | $3M | $501.0K | $-355.0K | $2M | $-8M | $1M | |
| Net Income | $-8M | $-11M | $-1M | $-8M | $-14M | $-16M | $-49M | $-25M | $2M | $-10M | $-6M | $-19M | $-18M | $-16M | $856.0K | $-5M | |
| EPS (Basic) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| EPS (Diluted) | $-0.02 | $-0.03 | $0.00 | $-0.02 | $-0.03 | $-0.04 | $-0.12 | $-0.06 | $0.00 | $-0.02 | $-0.02 | $-0.05 | $-0.04 | $-0.04 | $0.01 | $-0.01 | |
| Shares (Basic) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,210,000 | 411,150,000 | 410,851,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| Shares (Diluted) | 416,444,000 | 419,054,000 | -828,446,000 | 415,531,000 | 414,477,000 | 413,422,000 | -821,754,000 | 411,150,000 | 411,395,000 | 410,146,000 | -814,787,000 | 408,417,000 | 407,848,000 | 406,177,000 | -799,451,000 | 404,614,000 | |
| EBITDA | $-12M | $-11M | · | $-11M | $-16M | $-17M | · | $-25M | $-524.0K | $-14M | · | $-21M | $-24M | $-17M | · | $-5M |
Stato Patrimoniale 24
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144M | $131M | $135M | $123M | $148M | $120M | $121M | $157M | $216M | $214M | · | $271M | $233M | $191M | · | $240M | |
| Short-term Investments | $171M | $177M | $168M | $164M | $151M | $162M | $173M | $149M | $91M | $94M | · | $50M | $80M | $113M | · | $63M | |
| Receivables | $93M | $108M | $127M | $127M | $119M | $107M | $122M | $113M | $124M | $116M | · | $122M | $123M | $133M | · | $123M | |
| Inventory | $164M | $184M | $196M | $185M | $171M | $159M | $166M | $224M | $239M | $255M | · | $254M | $227M | $226M | · | $228M | |
| Prepaid Expense | $31M | $26M | $24M | $29M | $17M | $25M | $13M | $7M | $32M | $8M | · | $19M | $43M | $20M | · | $28M | |
| Current Assets | $603M | $626M | $650M | $628M | $607M | $573M | $595M | $650M | $702M | $688M | · | $718M | $706M | $684M | · | $687M | |
| PP&E (Net) | · | · | $12.0K | $13.0K | $14.0K | $15.0K | $16.0K | $24.0K | $49.0K | $81.0K | · | $147.0K | $179.0K | $187.0K | · | $999.0K | |
| PP&E (Gross) | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $12M | $13M | $13M | $14M | $15M | $16M | $16M | $17M | $18M | $19M | · | $20M | $20M | $21M | · | $22M | |
| Other Non-current Assets | $4M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $2M | $2M | · | $456.0K | |
| Total Assets | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Accounts Payable | $19M | $48M | $45M | $37M | $45M | $46M | $40M | $41M | $54M | $68M | · | $53M | $54M | $59M | · | $93M | |
| Current Liabilities | $164M | $180M | $194M | $182M | $186M | $162M | $180M | $202M | $231M | $224M | · | $267M | $271M | $244M | · | $287M | |
| Capital Leases | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $8M | · | $9M | $9M | $10M | · | $10M | |
| Other Non-current Liabilities | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $9M | $9M | $9M | · | $7M | $7M | $9M | · | $10M | |
| Total Liabilities | $181M | $196M | $211M | $201M | $205M | $182M | $199M | $219M | $248M | $244M | · | $286M | $291M | $275M | · | $320M | |
| Common Stock | $315M | $314M | $310M | $310M | $309M | $308M | $305M | $305M | $305M | $305M | · | $302M | $302M | $301M | · | $299M | |
| Paid-in Capital | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.92B | $1.91B | $1.91B | $1.91B | $1.90B | · | $1.90B | $1.89B | $1.89B | · | $1.88B | |
| Retained Earnings | $-1.73B | $-1.72B | $-1.71B | $-1.71B | $-1.70B | $-1.68B | $-1.67B | $-1.62B | $-1.59B | $-1.60B | · | $-1.58B | $-1.56B | $-1.54B | · | $-1.53B | |
| Treasury Stock | $69M | $69M | $67M | $67M | $67M | $66M | $65M | $65M | $65M | $65M | · | $64M | $63M | $63M | · | $62M | |
| Stockholders' Equity | $444M | $449M | $459M | $459M | $465M | $474M | $486M | $531M | $552M | $546M | $552M | $553M | $569M | $585M | $595M | $588M | |
| Liabilities + Equity | $624M | $646M | $671M | $660M | $670M | $656M | $685M | $751M | $800M | $790M | · | $839M | $860M | $860M | · | $908M | |
| Shares Outstanding | 420,044,022 | 419,594,602 | 416,214,102 | 415,965,977 | 415,401,497 | 414,365,189 | 411,584,851 | 411,261,678 | 411,113,770 | 410,735,780 | · | 408,551,020 | 408,133,807 | 407,265,944 | 408,824,093 | 403,828,955 |
Flusso di cassa 9
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $6M | $4M | $3M | $5M | $4M | $5M | $5M | $4M | $2M | $6M | $7M | $5M | |
| Amort. of Intangibles | $636.0K | $637.0K | $701.0K | $866.0K | $728.0K | $729.0K | $729.0K | $728.0K | $729.0K | $729.0K | $701.0K | $701.0K | $701.0K | $702.0K | $636.0K | $636.0K | |
| Restructuring | $40.0K | $3M | $4M | $9M | $23M | · | · | · | · | · | $229.0K | $711.0K | $10M | · | $-180.0K | $3M | |
| Operating Cash Flow | $7M | $6M | $15M | $-13M | $17M | $-12M | $-13M | $-2M | $-3M | $-13M | $-645.0K | $7M | $7M | $-7M | $2M | $-18M | |
| Investing Cash Flow | $6M | $-8M | $-4M | $-12M | $12M | $12M | $-23M | $-57M | $5M | $29M | $-71M | $31M | $34M | $-20M | $-28M | $31M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | $0 | · | · | · | $0 | |
| Financing Cash Flow | $-247.0K | $-2M | $-4.0K | $-248.0K | $-663.0K | $-1M | $17.0K | $-68.0K | $34.0K | $-1M | $83.0K | $-277.0K | $60.0K | $364.0K | $38.0K | $-156.0K | |
| Net Change in Cash | $12M | $-4M | $12M | $-25M | $28M | $-2M | $-36M | $-59M | $2M | $15M | $-72M | $38M | $42M | $-26M | $-26M | $12M | |
| Taxes Paid | $1M | $2M | $1M | $-1.0K | $-169.0K | $22.0K | $6M | $-1M | $-698.0K | $29.0K | $3M | $-432.0K | $-633.0K | $38.0K | $-292.0K | $622.0K |
Redditività 8
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 39.4% | · | 44.7% | 69.2% | 59.8% | · | 38.5% | 63.4% | 56.5% | · | 45.1% | 53.2% | 55.8% | · | 69.9% | |
| Operating Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| Net Margin | -18.1% | -23.3% | · | -15.6% | -19.4% | -37.4% | · | -59.4% | 2.3% | -17.6% | · | -29.2% | -21.9% | -19.1% | · | -5.7% | |
| Pretax Margin | -18.6% | -19.3% | · | -16.3% | -18.5% | -32.4% | · | -50.9% | 4.3% | -15.3% | · | -28.5% | -22.4% | -16.9% | · | -4.3% | |
| EBITDA Margin | -28.4% | -25.1% | · | -22.4% | -22.0% | -39.9% | · | -59.5% | -0.78% | -24.0% | · | -32.5% | -29.9% | -20.2% | · | -5.7% | |
| ROA | -1.2% | -1.6% | · | -1.1% | -1.9% | -2.2% | · | -3.2% | 0.18% | -1.2% | · | -2.2% | -1.9% | -1.8% | · | -0.53% | |
| ROE | -1.7% | -2.3% | · | -1.6% | -2.8% | -3.1% | · | -4.6% | 0.27% | -1.8% | · | -3.4% | -3.1% | -2.7% | · | -0.84% | |
| ROIC | -2.6% | -3.0% | · | -2.3% | -3.6% | -4.1% | · | -5.5% | -0.05% | -2.9% | · | -4.0% | -4.1% | -3.4% | · | -1.2% |
Liquidità e Solvibilità 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 3.5 | · | 3.4 | 3.3 | 3.5 | · | 3.2 | 3.0 | 3.1 | · | 2.7 | 2.6 | 2.8 | · | 2.4 | |
| Quick Ratio | 2.5 | 2.3 | · | 2.3 | 2.2 | 2.4 | · | 2.1 | 1.9 | 1.9 | · | 1.7 | 1.6 | 1.8 | · | 1.5 |
Efficienza 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.4 | 0.6 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.7 | · | 0.7 |
Valutazione (TTM) 9
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $210M | $210M | · | $207M | $225M | $208M | · | $232M | $270M | $289M | · | $322M | $350M | $365M | · | $421M | |
| Net Income TTM | $-40M | $-48M | · | $-63M | $-53M | $-49M | · | $-53M | $-45M | $-63M | · | $-58M | $-109M | $-123M | · | $-120M | |
| Market Cap | $6.70B | $6.07B | · | $6.81B | $6.74B | $3.73B | · | $5.18B | $5.67B | $7.31B | · | $7.52B | $9.71B | $12.22B | · | $8.80B | |
| P/E | -159.4 | -120.5 | · | -109.2 | -124.8 | -75.0 | · | -96.9 | -125.5 | -118.7 | · | -131.4 | -88.1 | -96.8 | · | -72.7 | |
| P/S | 31.9 | 29.0 | · | 33.0 | 30.0 | 17.9 | · | 22.3 | 21.0 | 25.3 | · | 23.3 | 27.7 | 33.5 | · | 20.9 | |
| P/B | 15.1 | 13.5 | · | 14.8 | 14.5 | 7.9 | · | 9.8 | 10.3 | 13.4 | · | 13.6 | 17.1 | 20.9 | · | 15.0 | |
| P / Tangible Book | 15.5 | 13.9 | · | 15.3 | 15.0 | 8.1 | · | 10.1 | 10.6 | 13.9 | · | 14.1 | 17.7 | 21.7 | · | 15.5 | |
| P / Cash Flow | · | 949.8 | · | · | · | -299.3 | · | · | · | -580.2 | · | · | · | -1743.4 | · | · | |
| Earnings Yield | -0.63% | -0.83% | · | -0.92% | -0.80% | -1.3% | · | -1.0% | -0.80% | -0.84% | · | -0.76% | -1.1% | -1.0% | · | -1.4% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $214M | $229M | $307M | $369M | $583M |
| Margine Lordo % | 56.6% | 35.6% | 53.9% | — | — |
| Margine Operativo % | -23.5% | -40.2% | -22.0% | — | — |
| Utile netto | $-39M | $-82M | $-59M | $-106M | $8M |
| EPS Diluito | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 3.3 | 3.3 | 2.8 | — | — |
| Quick Ratio | 2.2 | 2.3 | 1.8 | — | — |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 90 filer · $59.1M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 23 (+15 vs trimestre precedente) | 7 (-12 vs trimestre precedente) | 19 (+1 vs trimestre precedente) | 10 (-3 vs trimestre precedente) | +89K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Sarissa Capital Management LP | $26.673.916 | 1.673.395 | 45,11% | Azioni |
| Kynam Capital Management, LP | $8.495.733 | 532.982 | 14,37% | Azioni |
| Waterfront Wealth Inc. | $3.183.561 | 213.949 | 5,38% | Azioni |
| Brooklands Fund Management Ltd | $2.741.449 | 177.325 | 4,64% | Azioni |
| Eversept Partners, LP | $2.316.018 | 145.296 | 3,92% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $1.845.980 | 115.808 | 3,12% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $1.602.145 | 100.511 | 2,71% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $1.144.699 | 71.813 | 1,94% | Azioni |
| CITADEL ADVISORS LLC | $971.671 | 60.958 | 1,64% | Azioni |
| LCM Capital Management Inc | $818.710 | 51.362 | 1,38% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $771.002 | 48.369 | 1,30% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $765.120 | 48.000 | 1,29% | Opzione Call |
| George Kaiser Family Foundation | $593.080 | 37.207 | 1,00% | Azioni |
| JANE STREET GROUP, LLC | $523.294 | 32.829 | 0,89% | Azioni |
| TWO SIGMA ADVISERS, LP | $516.265 | 36.995 | 0,87% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $462.276 | 29.001 | 0,78% | Azioni |
| STATE STREET CORP | $398.755 | 25.016 | 0,67% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $385.748 | 24.200 | 0,65% | Opzione Put |
| Bleakley Financial Group, LLC | $374.670 | 23.505 | 0,63% | Azioni |
| State of New Jersey Common Pension Fund D | $300.931 | 18.879 | 0,51% | Azioni |
| CITADEL ADVISORS LLC | $299.672 | 18.800 | 0,51% | Opzione Put |
| COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | $292.818 | 18.370 | 0,50% | Azioni |
| R Squared Ltd | $269.992 | 16.938 | 0,46% | Azioni |
| State of Tennessee, Department of Treasury | $239.164 | 15.004 | 0,40% | Azioni |
| MORGAN STANLEY | $237.618 | 14.907 | 0,40% | Azioni |
| Quadrature Capital Ltd | $236.581 | 14.842 | 0,40% | Azioni |
| Quinn Opportunity Partners LLC | $228.022 | 14.305 | 0,39% | Azioni |
| Cubist Systematic Strategies, LLC | $224.390 | 13.699 | 0,38% | Azioni |
| EntryPoint Capital, LLC | $194.882 | 12.226 | 0,33% | Azioni |
| Jump Financial, LLC | $191.407 | 12.008 | 0,32% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $187.629 | 11.771 | 0,32% | Azioni |
| WELLS FARGO & COMPANY/MN | $179.564 | 11.265 | 0,30% | Azioni |
| NJ State Employees Deferred Compensation Plan | $178.542 | 10.900 | 0,30% | Azioni |
| Verdad Advisers, LP | $166.270 | 10.431 | 0,28% | Azioni |
| CITADEL ADVISORS LLC | $164.182 | 10.300 | 0,28% | Opzione Call |
| Steward Partners Investment Advisory, LLC | $142.025 | 8.910 | 0,24% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $121.224 | 7.605 | 0,21% | Azioni |
| OSAIC HOLDINGS, INC. | $104.537 | 6.559 | 0,18% | Azioni |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $92.038 | 5.774 | 0,16% | Azioni |
| MERCER GLOBAL ADVISORS INC /ADV | $80.099 | 5.025 | 0,14% | Azioni |
| UBS Group AG | $67.171 | 4.214 | 0,11% | Azioni |
| RHUMBLINE ADVISERS | $59.498 | 3.733 | 0,10% | Azioni |
| NATIONAL BANK OF CANADA /FI/ | $40.137 | 2.518 | 0,07% | Azioni |
| AMERIPRISE FINANCIAL INC | $30.318 | 1.902 | 0,05% | Azioni |
| ROYAL BANK OF CANADA | $28.000 | 1.787 | 0,05% | Azioni |
| GAMMA Investing LLC | $25.121 | 1.576 | 0,04% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $22.332 | 1.401 | 0,04% | Azioni |
| NewEdge Advisors, LLC | $21.471 | 1.347 | 0,04% | Azioni |
| Farther Finance Advisors, LLC | $15.271 | 958 | 0,03% | Azioni |
| BlackRock, Inc. | $13.677 | 858 | 0,02% | Azioni |
| IFP Advisors, Inc | $12.975 | 814 | 0,02% | Azioni |
| Beaird Harris Wealth Management, LLC | $11.955 | 750 | 0,02% | Azioni |
| ACADIAN ASSET MANAGEMENT LLC | $11.467 | 720.984 | 0,02% | Azioni |
| CoreCap Advisors, LLC | $8.528 | 535 | 0,01% | Azioni |
| Integrated Wealth Concepts LLC | $8.449 | 530 | 0,01% | Azioni |
| JONES FINANCIAL COMPANIES LLLP | $7.844 | 493 | 0,01% | Azioni |
| BARCLAYS PLC | $4.862 | 305 | 0,01% | Azioni |
| JPMORGAN CHASE & CO | $3.853 | 242 | 0,01% | Azioni |
| CWM, LLC | $3.644 | 252 | 0,01% | Azioni |
| Westside Investment Management, Inc. | $3.268 | 205 | 0,01% | Azioni |
| Global Retirement Partners, LLC | $2.646 | 166 | 0,00% | Azioni |
| GROUP ONE TRADING LLC | $2.072 | 130 | 0,00% | Azioni |
| HARBOUR INVESTMENTS, INC. | $1.562 | 98 | 0,00% | Azioni |
| Federation des caisses Desjardins du Quebec | $1.435 | 90 | 0,00% | Azioni |
| Activest Wealth Management | $797 | 50 | 0,00% | Azioni |
| HighMark Wealth Management LLC | $797 | 50 | 0,00% | Azioni |
| Arax Advisory Partners | $685 | 43 | 0,00% | Azioni |
| Darwin Wealth Management, LLC | $398 | 25 | 0,00% | Azioni |
| Continuum Advisory, LLC | $303 | 19 | 0,00% | Azioni |
| Caitong International Asset Management Co., Ltd | $271 | 17 | 0,00% | Azioni |
| SEI INVESTMENTS CO | $260 | 16 | 0,00% | Azioni |
| Hayek Kallen Investment Management | $204 | 12.809 | 0,00% | Azioni |
| Atlantic Union Bankshares Corp | $192 | 12 | 0,00% | Azioni |
| Truvestments Capital LLC | $191 | 12 | 0,00% | Azioni |
| Parallel Advisors, LLC | $159 | 10 | 0,00% | Azioni |
| Creative Capital Management Investments LLC | $143 | 9 | 0,00% | Azioni |
| Key Financial Inc | $128 | 8 | 0,00% | Azioni |
| CITIGROUP INC | $128 | 8 | 0,00% | Azioni |
| MCGUIRE CAPITAL ADVISORS INC | $112 | 7 | 0,00% | Azioni |
| EASTERN BANK | $112 | 7 | 0,00% | Azioni |
| Lindbrook Capital, LLC | $90 | 200 | 0,00% | Azioni |
| Oakmont Advisory Group, LLC | $80 | 5 | 0,00% | Azioni |
| Allworth Financial LP | $80 | 5 | 0,00% | Azioni |
| Crewe Advisors LLC | $80 | 5 | 0,00% | Azioni |
| BFSG, LLC | $80 | 5 | 0,00% | Azioni |
| SBI Securities Co., Ltd. | $80 | 5 | 0,00% | Azioni |
| WHITTIER TRUST CO | $63 | 4 | 0,00% | Azioni |
| Caitlin John, LLC | $32 | 2 | 0,00% | Azioni |
| WHITTIER TRUST CO OF NEVADA INC | $15 | 1 | 0,00% | Azioni |
| JFS WEALTH ADVISORS, LLC | $15 | 1 | 0,00% | Azioni |
Insider aziendali 37 insider · 17 dirigenti · 22 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Aaron Berg | President and CEO | 26 Giugno 2026 M | 85.648 | 0 | 0 | $0 |
| Patrick Holt | President and CEO | 22 Gennaio 2024 P | 314.426 | 0 | 0 | $0 |
| Karim Mikhail | President and CEO | 21 Febbraio 2023 A | 283.507 | 0 | 0 | $0 |
| John F Thero | President and CEO | 19 Novembre 2019 S | 2.342.285 | 0 | 0 | $0 |
| Peter L. Fishman | SVP, CFO | 01 Agosto 2026 A | 7.619 | 0 | 0 | $0 |
| Thomas Charles Reilly | EVP and CFO | 01 Luglio 2024 M | 94.305 | 0 | 0 | $0 |
| Michael Wayne Kalb | SVP and CFO | 16 Dicembre 2019 M | 21.552 | 0 | 0 | $0 |
| David Paul Keenan | EVP, Chief Operating Officer | 01 Luglio 2026 A | 13.470 | 0 | 0 | $0 |
| Jonathan Provoost | EVP, Chief Legal Officer | 01 Luglio 2026 A | 4.624 | 0 | 0 | $0 |
| Steven B Ketchum | EVP, Chief Scientific Officer | 01 Luglio 2026 A | 42.680 | 0 | 0 | $0 |
| Joseph T Kennedy | General Counsel | 07 Ottobre 2019 F | 125.723 | 0 | 0 | $0 |
| Mark Salyer | Chief Commercial Officer | 01 Febbraio 2018 A | — | 0 | 0 | $0 |
| Michael James Farrell | VP, Finance | 01 Febbraio 2016 A | 30.190 | 0 | 0 | $0 |
| Paul Huff | Chief Commercial Officer | 26 Luglio 2012 A | 0 | 0 | 0 | $0 |
| Stuart D Sedlack | Senior Vice President | 26 Luglio 2012 A | 0 | 0 | 0 | $0 |
| Paresh Soni | SVP and Head of Development | 01 Febbraio 2012 A | 0 | 0 | 0 | $0 |
| Frederick W Ahlholm | Vice President Finance | 01 Febbraio 2012 A | 0 | 0 | 0 | $0 |
| Oliver O'Connor | Direttore | 18 Aprile 2026 M | 801 | 0 | 0 | $0 |
| Paul Cohen | Direttore | 18 Aprile 2026 M | 836 | 0 | 0 | $0 |
| Diane E. Sullivan | Direttore | 18 Aprile 2026 M | 836 | 0 | 0 | $0 |
| Louis Sterling III | Direttore | 18 Aprile 2026 M | 4.049 | 0 | 0 | $0 |
| Patrice Eadon Bonfiglio | Direttore | 18 Aprile 2026 M | 836 | 0 | 0 | $0 |
| Keith Horn | Direttore | 18 Aprile 2026 M | 836 | 0 | 0 | $0 |
| Odysseas D Kostas | Direttore | 18 Aprile 2026 M | 836 | 0 | 0 | $0 |
| Mark Dipaolo | Direttore | 18 Aprile 2025 M | 401 | 0 | 0 | $0 |
| Olsen Per Wold | Direttore | 10 Gennaio 2023 M | 171.027 | 0 | 0 | $0 |
| David M Stack | Direttore | 04 Giugno 2021 P | 40.000 | 0 | 0 | $0 |
| Joseph S Zakrzewski | Direttore | 03 Gennaio 2020 M | 84.547 | 0 | 0 | $0 |
| Lars Ekman | Direttore | 12 Novembre 2019 M | 0 | 0 | 0 | $0 |
| Kristine Peterson | Direttore | 20 Maggio 2019 A | 0 | 0 | 0 | $0 |
| Patrick J O'Sullivan | Direttore | 20 Maggio 2019 A | — | 0 | 0 | $0 |
| VAN HEEK G JAN | Direttore | 20 Maggio 2019 A | 14.168 | 0 | 0 | $0 |
| Dr. James I. Healy | Direttore | 11 Luglio 2016 A | 90.000 | 0 | 0 | $0 |
| GORDON CARL L | Direttore | 04 Settembre 2012 S | 5.700 | 0 | 0 | $0 |
| Joseph Anderson | Direttore | 10 Luglio 2012 A | 11.683 | 0 | 0 | $0 |
| David W Feigal Jr | Direttore | 12 Luglio 2011 A | — | 0 | 0 | $0 |
| Abingworth LLP | Proprietario del 10% | 19 Aprile 2012 S | 1.599.168 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 34 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Sarissa Capital Management LP, Alexander J Denner ×3 depositi | 25 Marzo 2025 | 8,08% | Modifica | Campagna per il consiglio di amministrazione | SEC |
| 28 Febbraio 2023 | — | Deposito iniziale | — | SEC | |
| 27 Febbraio 2023 | — | Deposito iniziale | — | SEC | |
| 21 Febbraio 2023 | — | Deposito iniziale | — | SEC | |
| OR ×6 depositi | 15 Febbraio 2023 | — | Deposito iniziale | — | SEC |
| 14 Febbraio 2023 | — | Deposito iniziale | — | SEC | |
| 10 Febbraio 2023 | — | Deposito iniziale | — | SEC | |
| 19 Gennaio 2023 | — | Deposito iniziale | — | SEC | |
| 16 Giugno 2022 | — | Deposito iniziale | — | SEC | |
| Sofinnova Venture Partners VII, L.P. (“SVP VII”), Sofinnova Management VII, L.L.C. (“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Eric P. Buatois (“Buatois”) ×4 depositi | 23 Agosto 2013 | — | Deposito iniziale | Investimento passivo | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures V Co-Invest Growth Equity Fund LP 98-057-9772, Abingworth Bioventures V L.P. 98-051-8587, Abingworth Bioequities Master Fund Limited 66-066-0960 ×10 depositi | 22 Luglio 2013 | — | Deposito iniziale | Campagna per il consiglio di amministrazione | SEC |
| Boxer Capital, LLC, Boxer Asset Management Inc., Joseph Lewis ×4 depositi | 24 Agosto 2011 | — | Deposito iniziale | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP III LLC, Samuel D. Isaly ×14 depositi | 28 Aprile 2011 | — | Deposito iniziale | — | SEC |
| Fountain Healthcare Partners Fund 1, L.P. (“ Fountain ”), Fountain Healthcare Partners Ltd., Manus Rogan, Aidan King, Ena Prosser, Justin Lynch ×2 depositi | 10 Dicembre 2010 | — | Deposito iniziale | — | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) | 26 Ottobre 2010 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.